Do pylarify imaging agent - IC
Ended Awarded Last action
- Contract number
- 36C26325F0002
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 23
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $552,534
Award facts
- Contract value 97% obligated
-
- $552,534.16 Current, with exercised options
- $570,744.66 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$78,992 | |
| Original award | $631,526 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23) awarded a delivery order to Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY imaging agent on October 1, 2024. This $570,744.66 firm fixed-price delivery order, with an ultimate completion date of August 31, 2025, represents a non-competitive procurement issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside designation. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection, localization, and imaging of prostate cancer, providing critical diagnostic capabilities for federal healthcare providers serving veterans. Performance of this delivery order will occur at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts.
This award is part of Progenics Pharmaceuticals' extensive federal contracting portfolio with the Veterans Health Administration, through which the company has received over 150 individual contract awards across multiple Veterans Integrated Service Networks. The company maintains substantial indefinite delivery vehicles with the VA system, including a $290 million Federal Supply Schedule contract with VISN 12 established in April 2025 through March 31, 2030, which serves as the overarching master vehicle enabling efficient procurement of PYLARIFY radiopharmaceuticals across the federal healthcare system. The firm fixed-price structure ensures cost certainty for the government while supporting comprehensive prostate cancer diagnostic imaging programs at VA medical facilities nationwide.
Quick answers
Who was awarded contract 36C26325F0002?
36C26325F0002 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 23 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C26325F0002 worth?
The government has obligated $552,534 on 36C26325F0002. Its potential value, with all options, is $570,745.
Is contract 36C26325F0002 an order under another contract?
Yes. 36C26325F0002 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26325F0002 competed?
The extent of competition for 36C26325F0002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award